Skip to main content
OpenTrials
Completed

NCT Number: NCT03708991

Effectiveness of PGT-A: IVF Versus ICSI

The investigators want to investigate if the use of conventional in vitro fertilization (IVF) can generate more euploid embryos as compared to intracytoplasmic sperm injection (ICSI).

To verify this, the investigators will inject half of the oocytes by ICSI and the other half of the oocytes will be inseminated by conventional IVF. The most important aim is to see if IVF is able to generate more euploid embryos.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IVI RMA Abu Dhabi

Abu Dhabi, United Arab Emirates

About this study

ICSI is commonly used in pre-implantation genetic testing (PGT) cases to eliminate any risk of sperm DNA contamination. With the switch from cleavage stage biopsy to biopsy of the full (hatching) blastocyst, this potential risk of contamination can be neglected and could allow the use of conventional IVF in PGT cases. Especially in cases of non-male factor infertility, the use of conventional IVF can be applied as a more 'natural' insemination method.

The investigators will perform a pilot study on sibling oocytes including participants with non-male factor infertility and requesting PGT-A (PGT for aneuploidy). If at least 10 cumulus oocyte complexes (COCs) are obtained after oocyte retrieval, half of the oocytes will be subjected to ICSI and the other half to conventional IVF. Preimplantation development is followed by time lapse imaging and blastocysts (day 5-7) fulfilling the biopsy criteria will undergo trophectoderm biopsy to detect the ploidy state and the mitochondrial DNA (mtDNA) copy number.

The main objective is to analyse if the use a more physiological insemination method (IVF) has a beneficial impact on the ploidy state of the blastocyst as compared to ICSI within the same participant. As the embryos will be cultured in a time lapse imaging system, annotations can be made and the differences in maturation rate, fertilization rate and embryo development between both insemination methods can be analysed as secondary outcome parameter. On top of this, the PGT-A outcome will also display the mtDNA copy number which can be compared between IVF and ICSI biopsied sibling blastocyst. Euploid blastocysts will be transferred in subsequent frozen embryo transfer (FET) cycles and give an indication on the clinical outcome between IVF and ICSI.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sperm parameters Sperm concentration before capacitation: >15*106 per ml (WHO) Total motility (PR+NP,%): >40 (WHO) Progressive motility (PR,%):>32 (WHO) Sperm concentration after capacitation: >0.6*106 per ml (not WHO defined) Progressive motility (PR,%):>65 (WHO)
  • ≥10 COCs after oocyte retrieval
  • BMI ≤30 kg/m2
  • Female age 18 to ≤ 40 years
  • All ovarian stimulation protocols
  • Fresh ejaculates
  • Presence or absence of sperm morphology data: as the investigators do not have a diagnostic sperm analysis for all participants, the presence or absence of >4% normal morphology (WHO) will not be taken into account, even with known low (<4%) normal morphology
  • Couples requesting PGT-A
  • Arab population

Exclusion criteria

  • If after denudation (ICSI) only 2 mature oocytes are obtained
  • If all time lapse spaces are occupied
  • If the volume to be added after IVF is insufficient to perform IVF on all needed oocytes
  • Presence of >1 *106 per ml round cells in the ejaculate
  • If a couple's previous cycle was included in the study

Treatment and study plan

IVF combined with PGT-A

Diagnostic Test

trophectoderm biopsy to test the ploidy state of the IVF embryos

ICSI combined with PGT-A

Diagnostic Test

trophectoderm biopsy to test the ploidy state of the ICSI embryos

Primary outcomes

  1. Ploidy state: euploid or aneuploid

    Time frame: 7 days

    trophectoderm biopsy performed between day 5-7 of preimplantation development. These cells will be genetically tested to see if the correct number of chromosomes are present. Euploid embryos can be used for the patient, aneuploid embryos cannot be used for the patient.

Secondary outcomes

  1. mitoscore value: ranges from 10-1500

    Time frame: 1 day

    the trophectoderm biopsy sample is used to calculate a value indicating the mitochondrial DNA present in the biopt. Lower values are known to be linked to higher implantation rates of the corresponding blastocyst. Higher values have been correlated to aneuploidy.

  2. Maturation rate

    Time frame: 1 day

    The maturation rate is defined as the number of mature oocytes obtained per cumulus complex retrieved for the participants.A mature oocyte is defined as an oocyte that has extruded his fiist polar body and this mature oocyte is ready to be fertilized by the participants sperm.

  3. Morphokinetic development

    Time frame: 7 days

    As embryos are cultured in a time lapse imaging system, pictures will be taken every 20 minutes to follow the development. Each time that the embryos divides, the timing will be registered in the database. Like this, every division made by every embryo is recorded. the time the embryo needs to go from 1 cell to 2 cells, from 2 cells to 3 cells and so on.

  4. Fertilization rate

    Time frame: 1 day

    Fertilization is calculated on all mature oocytes or on all complexes obtained after oocyte retrieval. The fertilization rate is assessed by the presence of a male and a female pronucleus 16-20 hours post fertilization. If the oocyte is fertilized, the outcome is positive, if the oocyte is not fertilized, the outcome is negative.

  5. Embryo development up to day 3

    Time frame: 3 days

    For all normally fertilized oocytes the further development will be assessed as the embryos are cultured in a time lapse system. This system takes pictures of the embryos every 20 minutes which shows the development of the embryo like a movie: every time that a cell divides, the hour at which it divides will be registered in the time lapse system. For each cell division, specific time frames have been described that link the embryo to develop into a blastocyst or that increases the chance of implantation. The embryo will be evaluated on day 3 and will receive an embryo score that is based on the number of cells, the appearance of the cells, fragmentation and embryo dysmorphisms. These will divide the embryo quality into 4 categories with category 1 being the highest quality and category 4 being the lowest quality. The more fragmentation and the higher the degree of dysmorphisms, the more the quality will shift to category 4.

  6. Blastulation rate

    Time frame: 7 days

    A blastocyst is an embryo in which a cavity is visible on day 5 of the embryo development. If the cavity is present the outcome is positive, if the cavity is absent, the outcome is negative The complete process in which the development of one embryo is followed from the day of injection up until day 7 is called the preimplantation development

  7. Embryo development up to day 5

    Time frame: 7 days

    On day 5 of development, a score is given to every embryo. This is based on the presence or absence of a cavity, the number of cells and how tight the cells are packed. The more cells, the higher the grade, if less cells are present, the grade is lower. Based on these parameters, a final grade is calculated (3 grades) with grade 1 being the highest score.

  8. Pregnancy outcome

    Time frame: 3 months

    pregnancy outcomes from the frozen embryo transfers: blood samples will be taken and the level of beta-hCG will be measured to define a pregnancy or no pregnancy. A pregnancy is defined as the best oucome. In case a pregnancy is obtained, the patient will come for an ultrasound scan between week 7-12 to checke the presence of a gestational sac and the presence of a fetal heart beat. The presence of a fetal heart beat is defined as a positive outcome, the absence is defined as a negative outcome.

Other outcomes

  1. sperm concentration

    Time frame: 1 day

    concentration will be analysed under a microscope in a Makler or Neubauer counting chamber that allows you to define the concentration of that specific sample: depending on the number of sperm cells counted per row or square in the chamber, the concentration can be calculated.

    Concentration will start at 15 million per milliliter in the original sperm and may be as high as 500 million per milliliter.

  2. sperm motility

    Time frame: 1 day

    The motility of the sperm will be analysed under a microscope in a Makler or Neubauer counting chamber that allows you to count the four different types of motility present in a sample.

    Sperm motility is defined as the number of sperm cells that are able to progress on their own and is expressed as a percentage: the higher the percentage, the better the value is.

  3. Controlled ovarian stimulation: dosage

    Time frame: 2 weeks

    In order to stimulate multiple follicular development, patients will be stimulated with fixed doses of hormones. The total dosage of hormones used will be registered.

  4. Controlled ovarian stimulation: days of stimulation

    Time frame: 2 weeks

    In order to stimulate multiple follicular development, patients will be stimulated with fixed doses of hormones. Once the follicular development is optimal (based on the number of follicles and the corresponding hormonal values) the patient can be triggered for final oocyte maturation. The total number of days needed during this stimulation will be registered.

  5. Controlled ovarian stimulation: hormonal profile

    Time frame: 2 weeks

    During the stimulation, the hormonal profile of every patient will be measured (estrogens, luteinizing hormone, progesterone): these blood values will be compared to the number of follicles that are measured in the participants and the combination of the three blood values should correspond to the sizes and numbers of follicles measured in the participants,

  6. Controlled ovarian stimulation: type of trigger

    Time frame: 2 weeks

    Once all follicles have reached the optimal size, the participants will be triggered for final oocyte maturation. The type of trigger that is administered will be recorded.

  7. Controlled ovarian stimulation: measurement of follicles

    Time frame: 2 weeks

    During the stimulation, the follicles present in the participants will grow steadily and the size of the follicles will be measured to ensure a good development (in combination with the hormonal profile). These follicles will be measured by vaginal echography.

Sponsors and collaborators

Lead sponsor

ART Fertility Clinics LLC

Other

Registry information

Official study title

Effectiveness of PGT-A by Using IVF Versus ICSI for Non-male Factor Infertility: a Pilot Study

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Oct 17, 2018
Registry last updated
Aug 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.